ARHGEF1: A Potential Drug Target and Biomarker (G9138)

Target Name: ARHGEF1

NCBI ID: G9138

ARHGEF1

ARHGEF1: A Potential Drug Target and Biomarker

ARHGEF1 (Rho guanine nucleotide exchange factor 1) is a protein that plays a critical role in the regulation of cell signaling pathways, including the GTPase signaling pathway. This protein is expressed in various tissues and cell types and is involved in the regulation of cell proliferation, differentiation, and survival. Therefore, ARHGEF1 has been considered as a potential drug target and biomarker.

Diseease and Potential Therapeutic Interventions

ARHGEF1 is often aberrantly expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The over-expression of ARHGEF1 has been associated with the development and progression of these diseases. Therefore, targeting ARHGEF1 as a drug target may provide new therapeutic interventions.

ARHGEF1 as a Drug Target

ARHGEF1 has been identified as a potential drug target due to its involvement in the regulation of cell signaling pathways. GTPase signaling is a critical pathway that regulates various cellular processes, including cell proliferation, differentiation, and survival. The regulation of GTPase signaling is crucial for the proper functioning of cells, and alterations in this pathway have been implicated in the development and progression of various diseases.

ARHGEF1 is involved in the regulation of GTPase signaling by activating the GTPase activity of various proteins, including Ca2+-dependent GTPases. Therefore, inhibiting ARHGEF1 activity may be a useful therapeutic intervention for diseases that are characterized by the over-expression of ARHGEF1.

ARHGEF1 as a Biomarker

ARHGEF1 has also been identified as a potential biomarker for various diseases. The over-expression of ARHGEF1 has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, measuring the expression level of ARHGEF1 may provide valuable information for the diagnosis and prognosis of these diseases.

In addition, the activity of ARHGEF1 has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. Therefore, measuring the activity of ARHGEF1 may also provide valuable insights into the mechanisms of these processes and their regulation.

Conclusion

In conclusion, ARHGEF1 is a protein that plays a critical role in the regulation of cell signaling pathways and has been identified as a potential drug target and biomarker. The over-expression of ARHGEF1 has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, targeting ARHGEF1 as a drug target or biomarker may provide new therapeutic interventions and insights into the mechanisms of these diseases. Further research is needed to fully understand the role of ARHGEF1 in the regulation of cell signaling pathways and its potential as a drug target and biomarker.

Protein Name: Rho Guanine Nucleotide Exchange Factor 1

Functions: Seems to play a role in the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 (GNA12) and alpha-13 (GNA13) subunits (PubMed:9641915, PubMed:9641916). Acts as GTPase-activating protein (GAP) for GNA12 and GNA13, and as guanine nucleotide exchange factor (GEF) for RhoA GTPase (PubMed:9641915, PubMed:9641916, PubMed:8810315, PubMed:30521495). Activated G alpha 13/GNA13 stimulates the RhoGEF activity through interaction with the RGS-like domain (PubMed:9641916). This GEF activity is inhibited by binding to activated GNA12 (PubMed:9641916). Mediates angiotensin-2-induced RhoA activation (PubMed:20098430)

The "ARHGEF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets